New CAR T-Cell Therapy Offers Hope for Relapsed or Refractory T-cell Leukaemia
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) is challenging to treat. Outcome for such patients is dismal. A recent experimental treatment – using CD7 CAR T-cell therapy, developed by N2CR member